secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inozyme Pharma, Inc. (—)
CIK:        0001693011
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0000950170-25-035939
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inozyme reports FY2024 net loss of $102M; cuts 25% workforce to focus on ENPP1 Deficiency
--------------------------------------------------------------------------------

- FY2024 net loss $102.0M ($1.62 per share) vs $71.2M ($1.37 per share) in 2023.
- Cash, equivalents & ST investments $113.1M; expects runway into Q1 2026 after prioritization.
- Workforce reduction of ~25%; $1.8M expected charges, substantially complete by Q3 2025.
- Completed enrollment in ENERGY 3 trial (N=27) for INZ-701; topline data expected Q1 2026.
- ABCC6 Deficiency and calciphylaxis trials postponed; only ongoing treatment for existing patients continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1693011/000095017025035939/0000950170-25-035939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1693011/000095017025035939/inzy-20250307.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-035939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer